Machine learning-assisted high-performance immunoSERS platform using silk fibroin as a natural etching mask for early diagnosis of Alzheimer's diseaseopen access
- Authors
- Lee, Soo Hyun; Kim, Soohyun; Lee, Jong Uk; Baek, Seung Jong; Hyun, Subin; Jung, Sunghoon; Yang, Jun-Yeong; Mun, ChaeWon; Lee, Seunghun; Lee, Chan-Nyoung; Park, Sung-Gyu; Sim, Sang Jun
- Issue Date
- Feb-2026
- Publisher
- Elsevier Ltd
- Keywords
- Alzheimer's disease; Immunoassay; Multivariate classification; Silk fibroin; Surface-enhanced Raman spectroscopy
- Citation
- Biosensors & Bioelectronics, v.294, pp 1 - 11
- Pages
- 11
- Indexed
- SCIE
SCOPUS
- Journal Title
- Biosensors & Bioelectronics
- Volume
- 294
- Start Page
- 1
- End Page
- 11
- URI
- https://scholarworks.dongguk.edu/handle/sw.dongguk/62245
- DOI
- 10.1016/j.bios.2025.118222
- ISSN
- 0956-5663
1873-4235
- Abstract
- Early and accurate diagnosis of Alzheimer's disease (AD) is a major stride toward pharmacological interventions to delay the onset or progression of the disease in patients with mild symptoms. In this study, we developed a silk fibroin-templated surface-enhanced Raman spectroscopy (SERS)-activated double-sandwich immunoassay (immunoSERS) platform that enhances plasmonic hotspot formation for the ultrasensitive detection of biomarkers. Silk fibroin, acting as a natural etching mask, facilitates the direct fabrication of Au nanocavity (AuNC) substrates and enables the immunoSERS platform to achieve attomolar-level detection (limit of detection: 35.8 aM) with high reproducibility (relative standard deviation: ∼2.5 %) due to its unique structural characteristics. This platform effectively detects four core AD biomarkers—amyloid beta 42 (Aβ42), total tau (t-tau), phosphorylated tau (p-tau), and brain-derived neurotrophic factor (BDNF)—in human plasma. Moreover, by introducing a k-nearest neighbors (KNN)-based machine learning algorithm, the suggested platform could classify disease progression stages with 94.0 % accuracy. These results indicate that this silk fibroin-driven immunoSERS platform is a viable alternative to existing diagnostic techniques for the effective early screening of AD and are a potential therapy to delay AD incidence in clinical practice. © 2025 Elsevier B.V.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Life Science and Biotechnology > Department of Biomedical Engineering > 1. Journal Articles

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.